Please assess the completion status of the following clinical trial:

Trial Title: Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Was either a P neonate born at least 27 weeks to less than 34 weeks of gestational age (GA) or a TNT neonate born at least 34 weeks but no more than 40 weeks of GA.~2. Was administered INOmax therapy after birth to 7 days of age via any route (invasive or noninvasive ventilation) for a minimum treatment period of at least 24 hours up to 96 ± 12 hours. The participants may receive INOmax for a longer period.~3. Had PH, as confirmed by echocardiogram or a differential saturation gradient of at least 10%.~4. Received INOmax administration as part of routine clinical practice in a Level III or higher neonatal intensive care unit in the United States.~5. Has all variables required to calculate OI or SOI (a baseline sample prior to treatment and 4 samples obtained during treatment).~Exclusion Criteria:~1. Was at risk of imminent death (death expected within 24 hours).~2. Received extracorporeal membrane oxygenation (ECMO).~3. Had a life-threatening abnormality (cranial, cardiac, thoracic), chromosomal abnormality, congenital diaphragmatic hernia, congenital heart defect (other than patent ductus arteriosus or small atrial septal defect).~4. Had been resuscitated requiring chest compressions within 6 hours of receiving INOmax.~5. Had Grade IV bilateral intraventricular hemorrhage or periventricular leukomalacia.~6. Had active uncontrolled bleeding.~7. Had disseminated intravascular coagulopathy.~8. Had active seizures while receiving anticonvulsants.~9. Experienced prolonged asphyxia with evidence of severe acidosis (pH \< 7.25).~10. Received concomitant pulmonary vasodilator therapy (eg, prostacyclin or sildenafil) except when sildenafil was used to wean the participant from INOmax therapy.

- Gender: ALL
- Minimum Age: 27 Weeks
- Maximum Age: 40 Weeks
- Healthy Volunteers: f

Study Arms:
- P Neonates (Type: None): Premature (P) neonates \[at least 27 weeks but less than 34 weeks of gestational age\]
- TNT Neonates (Type: None): Term-Near-Term (TNT) neonates at least 34 weeks of gestational age

Based on this trial design, predict the completion outcome and termination type (if applicable).